Furui Co.,Ltd(SZ:300049)2025-04-22 10:52Group 1: Financial Performance - In 2024, the company achieved total revenue of CNY 1.349 billion, a year-on-year increase of 16.93% [3] - The net profit attributable to shareholders was CNY 113 million, up 11.54% year-on-year [3] - The cash flow from operating activities was CNY 221 million, a decrease of 27.38% compared to the previous year [3] - For Q1 2025, total revenue was CNY 330 million, a year-on-year increase of 2.35%, while net profit decreased by 32.97% to CNY 28.64 million [3] Group 2: Business Segments - The medical device segment generated revenue of CNY 923 million, a growth of 10.98% year-on-year, with equipment sales contributing CNY 511 million (55.38%) and service fees CNY 412 million (44.62%) [3] - Echosens company reported a net profit of CNY 190.52 million, an increase of 8.26% year-on-year [3] - The company installed 651 units of FibroScan Go and box globally [3] Group 3: Strategic Goals - The vision is to establish a global consensus on liver fibrosis and become a specialized, international management medical group [4] - The mission is to help every family stay away from liver cancer [4] - The core strategy includes five projects: screening, diagnosis, treatment, management, and protection [4] Group 4: Market Opportunities - The Chinese health check market for liver elasticity testing has a potential space of CNY 100 billion [5] - The company aims to cover over 170 health check locations in collaboration with Aikang Guobin [5] - The U.S. market saw a 30% growth in Q1 2025, driven by the approval of the first MASH drug by the FDA [8] Group 5: Product and Service Innovations - The "Hui Gan Bao" insurance product is the first dedicated insurance for chronic liver disease patients, offering various benefits [7] - The company has established a three-tier defense system for liver disease management, focusing on prevention, precise diagnosis, and early treatment [6] - The accuracy of the company's diagnostic equipment exceeds 95%, establishing it as the gold standard for liver fibrosis diagnosis [6]